Detection technology and clinical applications of serum viral products of hepatitis B virus infection

被引:7
作者
Liu, Ying [1 ]
Wu, Di [1 ]
Zhang, Kui [2 ]
Ren, Rongrong [3 ]
Liu, Yuxuan [1 ]
Zhang, Shuya [1 ]
Zhang, Xuanyu [1 ]
Cheng, Jilin [4 ]
Chen, Liping [5 ]
Huang, Jun [1 ]
机构
[1] Zhengzhou Univ, Sch Life Sci, Zhengzhou, Henan, Peoples R China
[2] Southwest Univ, Coll Sericulture Text & Biomass Sci, State Key Lab Resource Insects, Chongqing, Peoples R China
[3] Zhejiang Hosp, Dept Clin Lab, Hangzhou, Zhejiang, Peoples R China
[4] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Dept Gastroenterol, Shanghai, Peoples R China
[5] Shanghai Geriatr Med Ctr, Dept Gastroenterol, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
HBV; serum viral products; detection technology; diagnosis; treatment; CORE-RELATED ANTIGEN; PREDICT HBEAG SEROCONVERSION; LINKED-IMMUNOSORBENT-ASSAY; REAL-TIME PCR; SURFACE-ANTIGEN; ENZYME-IMMUNOASSAY; MICROPARTICLE ENZYME; QUANTITATIVE ASSAY; IMMUNOGLOBULIN-G; RNA LEVELS;
D O I
10.3389/fcimb.2024.1402001
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Viral hepatitis, caused by its etiology, hepatitis virus, is a public health problem globally. Among all infections caused by hepatitis-associated viruses, hepatitis B virus (HBV) infection remains the most serious medical concern. HBV infection particularly affects people in East Asia and Africa, the Mediterranean region, and Eastern Europe, with a prevalence rate of > 2%. Currently, approximately 1 billion people worldwide are infected with HBV, and nearly 30% of them experience chronic infection. Chronic HBV infection can lead to chronic hepatitis B (CHB), liver cirrhosis, and hepatocellular carcinoma (HCC), resulting in the related death of approximately 1 million people annually. Although preventative vaccines and antiviral therapies are currently available, there is no cure for this infection. Clinical testing is not only the gateway for diagnosis of HBV infection, but also crucial for judging the timing of medication, evaluating the effect of antiviral therapy, and predicting the risk of relapse after drug withdrawal in the whole follow-up management of hepatitis B infected persons. With advances in detection technology, it is now possible to measure various viral components in the blood to assess the clinical status of HBV infection. Serum viral products of HBV infection, such as HBV DNA, HBV RNA, hepatitis B surface antigen, hepatitis B e-antigen, and hepatitis B core-related antigen, are non-invasive indicators that are critical for the rapid diagnosis and management of related diseases. Improving the sensitivity of monitoring of these products is essential, and the development of corresponding detection technologies is pivotal in achieving this goal. This review aims to offer valuable insights into CHB infection and references for its effective treatment. We provide a comprehensive and systematic overview of classical and novel methods for detecting HBV serum viral products and discusses their clinical applications, along with the latest research progress in this field.
引用
收藏
页数:14
相关论文
共 174 条
[1]   A critique and systematic review of the clinical utility of hepatitis B core-related antigen [J].
Adraneda, Celina ;
Tan, Yong Chuan ;
Yeo, Ee Jin ;
Kew, Guan Sen ;
Khakpoor, Atefeh ;
Lim, Seng Gee .
JOURNAL OF HEPATOLOGY, 2023, 78 (04) :731-741
[2]   Novel immunoassay for TSH measurement in rats [J].
Alves, Thalita G. ;
Melo, Maria Clara de C. ;
Kasamatsu, Teresa S. ;
Oliveira, Kelen C. ;
de Souza, Janaina Sena ;
da Conceicao, Rodrigo Rodrigues ;
Giannocco, Gisele ;
Dias-da-Silva, Magnus R. ;
Chiamolera, Maria Izabel ;
Vieira, Jose Gilberto .
ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2017, 61 (05) :460-463
[3]   Diagnostic accuracy of tests to detect hepatitis B surface antigen: a systematic review of the literature and meta-analysis [J].
Amini, Ali ;
Varsaneux, Olivia ;
Kelly, Helen ;
Tang, Weiming ;
Chen, Wen ;
Boeras, Debrah I. ;
Falconer, Jane ;
Tucker, Joseph D. ;
Chou, Roger ;
Ishizaki, Azumi ;
Easterbrook, Philippa ;
Peeling, Rosanna W. .
BMC INFECTIOUS DISEASES, 2017, 17
[4]  
Author Group of Expert Opinions, 2022, Zhonghua Gan Zang Bing Za Zhi, V30, P493, DOI 10.3760/cma.j.cn501113-20220416-00203
[5]   A protein's final ESCRT [J].
Babst, M .
TRAFFIC, 2005, 6 (01) :2-9
[6]   VIRAL-HEPATITIS, TYPE-B, IN EXPERIMENTAL-ANIMALS [J].
BARKER, LF ;
MAYNARD, JE ;
PURCELL, RH ;
HOOFNAGLE, JH ;
BERQUIST, KR ;
LONDON, WT .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1975, 270 (01) :189-195
[7]   Reply to: "Nucleos(t)ide analogue interruption: Alternative approach to intrahepatic set point for spontaneous control of HBV replication?" [J].
Berg, Thomas ;
Petersen, Joerg .
JOURNAL OF HEPATOLOGY, 2018, 68 (03) :611-612
[8]  
BLUMBERG BARUCH S., 1964, BULL N Y ACAD MED, V40, P377
[9]   A NEW ANTIGEN IN LEUKEMIA SERA [J].
BLUMBERG, BS ;
ALTER, HJ ;
VISNICH, S .
JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1965, 191 (07) :541-&
[10]   A SERUM ANTIGEN (AUSTRALIA ANTIGEN) IN DOWNS SYNDROME LEUKEMIA AND HEPATITIS [J].
BLUMBERG, BS ;
GERSTLEY, BJ ;
HUNGERFO.DA ;
LONDON, WT ;
SUTNICK, AI .
ANNALS OF INTERNAL MEDICINE, 1967, 66 (05) :924-+